CA
BCRX icon

Continuum Advisory’s BioCryst Pharmaceuticals BCRX Stock Holding History

Continuum Advisory’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7K Buy
+1,668
New +$15.1K ﹤0.01% 1096
2025
Q2 		– Sell
-1,668
Closed -$12.5K – 517
2025
Q1 		$12.5K Buy
1,668
+470
+39% +$3.79K ﹤0.01% 934
2024
Q4 		$9.01K Sell
1,198
-91
-7% -$691 ﹤0.01% 1016
2024
Q3 		$9.6K Buy
1,289
+91
+8% +$692 ﹤0.01% 1004
2024
Q2 		$7.4K Hold
1,198
– – ﹤0.01% 1015
2024
Q1 		$6.4K Buy
+1,198
New +$6.74K ﹤0.01% 1031

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Continuum Advisory's BCRX Position: Q2 2026 in Review

Continuum Advisory opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 1,668 shares worth $16.7K. The stake represents ﹤0.01% of the portfolio and ranks #1096 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in BCRX as recently as Q1 2025.

Continuum Advisory first reported a position in BCRX in Q1 2024 and has held it in 6 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Continuum Advisory held 1,668 shares of BioCryst Pharmaceuticals worth $16.7K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1096 holding.
  • Continuum Advisory first reported a position in BioCryst Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.